Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Gris-Oliver

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
JHEP Reports : Innovation in Hepatology|November 11, 2024
Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCCMarta Piqué-Gili, Carmen Andreu-Oller, Agavni Mesropian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2025
E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular CarcinomaAgavni Mesropian, Albert Gris-Oliver, Ugne Balaseviciute, et al.
Nature Communications|August 31, 2018
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancerIvana Zagorac, Sara Fernandez-Gaitero, Renske Penning, et al.
Nature Medicine|November 8, 2016
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancerFara Brasó-Maristany, Simone Filosto, Steven Catchpole, et al.
Nature Genetics|February 2, 2026
Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signalingAnagha Krishna, Alison Meynert, Karamjit Singh Dolt, et al.
The EMBO Journal|February 18, 2022
TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS-CoV-2 infectionRenée M van der Sluis, Lamin B Cham, Albert Gris-Oliver, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived XenograftsAlbert Gris-Oliver, Marta Palafox, Laia Monserrat, et al.
Cell Reports. Medicine|April 2, 2026
Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinomaElena Adan-Villaescusa, Borja Castello-Uribe, Iker Uriarte, et al.
Journal of Hepatology|December 21, 2024
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinomaSarah Cappuyns, Marta Piqué-Gili, Roger Esteban-Fabró, et al.
EMBO Molecular Medicine|November 1, 2018
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
JHEP Reports : Innovation in Hepatology|November 11, 2024
Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCCMarta Piqué-Gili, Carmen Andreu-Oller, Agavni Mesropian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2025
E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular CarcinomaAgavni Mesropian, Albert Gris-Oliver, Ugne Balaseviciute, et al.
Nature Communications|August 31, 2018
In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancerIvana Zagorac, Sara Fernandez-Gaitero, Renske Penning, et al.
Nature Medicine|November 8, 2016
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancerFara Brasó-Maristany, Simone Filosto, Steven Catchpole, et al.
Nature Genetics|February 2, 2026
Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signalingAnagha Krishna, Alison Meynert, Karamjit Singh Dolt, et al.
The EMBO Journal|February 18, 2022
TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS-CoV-2 infectionRenée M van der Sluis, Lamin B Cham, Albert Gris-Oliver, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived XenograftsAlbert Gris-Oliver, Marta Palafox, Laia Monserrat, et al.
Cell Reports. Medicine|April 2, 2026
Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinomaElena Adan-Villaescusa, Borja Castello-Uribe, Iker Uriarte, et al.
Journal of Hepatology|December 21, 2024
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinomaSarah Cappuyns, Marta Piqué-Gili, Roger Esteban-Fabró, et al.
EMBO Molecular Medicine|November 1, 2018
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationMarta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, et al.
Pageof 3